Variations in Diagnostic Criteria for Male Hypogonadism: Is There a Need for Standardizing Specialist Society Guidelines?

Nine major specialist societies disagree on the name, diagnostic cutoffs, and monitoring protocols for male hypogonadism

Journal: International Journal of Impotence Research | Published: 2025-07-19 | Type: Narrative Review | PMID: 40683978 Authors: Tsampoukas G (Homerton University Hospital, UK), Karna S (Milton Keynes University Hospital, UK), Morgado A (Centro Hospitalar Universitário São João, Porto), Minhas S (Imperial College NHS Trust, London) Funding/COI: Funding not disclosed. Two authors have direct EAU guideline involvement: Minhas (vice-chair, EAU Sexual and Reproductive Health) and Morgado (associate member) — potential bias toward EAU's framework in interpreting competing guidelines.

Summary

Nine major specialist societies — EAU, AUA, Endocrine Society, SfE, EAA, BSSM, SIAMS, SIE, and ISSM — cannot agree on what to call male hypogonadism, what testosterone threshold triggers the diagnosis, or how often to monitor PSA and hematocrit afterward. This narrative review maps those disagreements across all nine bodies and argues for an international consensus process. It does not resolve the disagreements; it catalogues them.

Claims

• Late-onset hypogonadism prevalence is approximately 2.1% in men aged 40–79, rising to as high as 30% in specific populations (none named in the abstract)
• The testosterone replacement therapy market is projected to reach $5.1 billion by 2030 (source not cited in abstract)
• Terminology splits along institutional lines: EAU, SfE, SIAMS, and SIE use "male hypogonadism," emphasizing testicular function; AUA, BSSM, and ISSM prefer "testosterone deficiency," emphasizing symptomatic low testosterone
• Diagnostic cutoffs for total and free testosterone diverge across societies, creating "gray zones" where a man qualifies for treatment under one guideline but not another
• Follow-up protocols for PSA and hematocrit monitoring also differ, with no cross-society consensus on frequency or thresholds

Study Quality

This is a narrative review — no preregistered protocol, no systematic search strategy, no PRISMA flow diagram. The authors selected which guidelines to discuss and how to frame the comparisons; that selection is inherently subjective. There is no quantification of how large the diagnostic cutoff gaps actually are (e.g., specific testosterone values in nmol/L or ng/dL are not provided in the abstract), which limits the reader's ability to judge clinical significance. The call for standardization is the authors' opinion, not a data-derived conclusion.

The $5.1 billion market projection appears without a citation in the abstract, a minor but telling lapse in a paper arguing for rigorous standards.

Red Flags

• COI is load-bearing: Two of four authors are embedded in EAU guideline bodies. A review that critiques nine competing frameworks — including AUA and EnS — while two authors hold EAU positions is not a neutral audit
• Narrative, not systematic: Author selection bias cannot be ruled out; papers or perspectives unfavorable to the authors' preferred framework may be underweighted
• No diagnostic numbers in abstract: A paper about divergent cutoffs that doesn't state the actual cutoffs is asking readers to trust the synthesis without checking it
• Funding undisclosed: A $5.1B market creates obvious industry interest in guideline definitions; not knowing who paid for this review is a genuine gap

Strengths

• Covers all nine major international guideline bodies in one place — useful reference landscape
• Identifies a real, documented clinical problem: a man can meet diagnostic criteria in London and fail them in Boston using the same blood test
• The COI is disclosed, not hidden — authors acknowledge it directly
• Authors have hands-on guideline experience, giving them genuine insider knowledge of why these gaps exist

Verdict

This paper is useful as a map, not as evidence. It documents a real dysfunction in the field — nine societies producing incompatible diagnostic frameworks for a condition affecting millions of men — but the narrative format and EAU-affiliated authorship mean you're reading one faction's account of a turf dispute. The absence of actual testosterone cutoff numbers in a paper explicitly about cutoff disagreements is a frustrating omission. Worth reading for the comparative table of society positions (presumably in the full text); not worth citing as an authoritative analysis of which approach is correct.